Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.

DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction Between EZH2 and DNMT3A.

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

3141 – LEUKEMIA-ASSOCIATED MUTATIONS IN DNMT3A MEDIATE SENSITIVITY TO REPLICATION STRESS INDUCED BY NUCLEOSIDE ANALOGS

Conditional Knockin Of Dnmt3a R878h Initiates Acute Myeloid Leukemia With Mtor Pathway Involvement

Significance of targeting DNMT3A mutations in AML

Dnmt3a Haploisufficiency Cooperates with Oncogenic Kras to Promote an Early-Onset T-Cell Leukemia

Targeting CaMKII-δ/DHCR24 Axis is a Novel Strategy Against Acute Myeloid Leukemia

DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming

Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway

NAM-NAD+-ADO metabolic reprogramming is a key factor for DNMT3A mutation to promote leukemia development through regulating cell cycle and immune microenvironment

Novel Impact Of The Dnmt3a R882h Mutation On Gsh Metabolism In A K562 Cell Model Established By Talens

DNMT3A Mutation Leads to Leukemic Extramedullary Infiltration Mediated by TWIST1

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

Dnmt3a Haploinsufficiency Cooperates with Oncogenic Kras to Promote an Early-Onset T-cell Acute Lymphoblastic Leukemia.

Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations

Cooperation of Dnmt3a R878H with Nras G12D Promotes Leukemogenesis in Knock-in Mice: a Pilot Study

P3.02-080 DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients

Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

Knock-In Of Dnmt3a R878h Recapitulates Human Acute Myeloid Leukemia Harboring Dnmt3a Mutation And Is Highly Responsive To Mtor Inhibitor Rapamycin

Dnmt3a Arg882 Mutation Drives Chronic Myelomonocytic Leukemia Through Disturbing Gene Expression/Dna Methylation in Hematopoietic Cells